

June 26, 2025

National Stock Exchange of India Limited, Exchange Plaza, Bandra Kurla Complex Bandra (E), Mumbai-400051 BSE Limited, Phiroze Jeejeebhoy Towers Dalal Street, Fort, Mumbai-400001

Symbol: **ORCHPHARMA**

Scrip Code: **524372**

Sub: Summary Proceedings of Hon'ble National Company Law Tribunal, Division Bench- II, Chennai (Hon'ble NCLT) convened meeting of equity shareholders of Orchid Pharma Limited ("Company"/ "Amalgamated Company") for considering and approving the Scheme of Amalgamation and Arrangement of Dhanuka Laboratories Limited ("Amalgamating Company") with Company and their respective shareholders and creditors ("the Scheme")

Dear Sir/Madam,

This is in furtherance to our earlier intimation on June 09, 2025, providing the Record date w.r.t. the meeting of equity shareholders of the Company.

In accordance to Regulation 30 read with Para A, Part A of Schedule III of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, please find enclosed herewith the summary of proceedings of the Hon'ble NCLT convened meeting of equity shareholders of the Company held on June 26, 2025.

You are requested to take the above information on record.

For Orchid Pharma Limited

Kapil Dayya Company Secretary & Compliance Officer M. No.: F10698

Enclosed: a/a

Orchid Pharma Limited Regd. Office: Plot Nos. 121-128, 128A-133, 138-151, 159-164, SIDCO Industrial Estate, Alathur, Chengalpattu Dist.- 603110, Tamil Nadu, India Phone: (91)-44-2744 4471/72/73 Email: Corporate@orchidpharma.com Website: www.orchidpharma.com CIN: L24222TN1992PLC022994



Summary of Proceedings of the meeting of equity shareholders of Orchid Pharma Limited ("Company") pursuant to the Order of Hon'ble National Company Law Tribunal, Division Bench- II, Chennai ("Hon'ble NCLT") held on Thursday, June 26, 2025 ("the Meeting")

Date, time and venue of the Meeting

The Meeting convened pursuant to the Order of Hon'ble NCLT dated April 29, 2025, read with revised order dated May 9, 2025 ("NCLT Order") was held on Thursday, June 26, 2025 at 12:30 p.m. (IST) through video conferencing/ other audio-visual means ("VC/OAVM").

Proceedings in brief

Mr. R. Varadharajan, Hon'ble NCLT appointed Chairperson for the Meeting chaired the Meeting.

The requisite quorum pursuant to Hon'ble NCLT order being not present, the meeting was adjourned by the Chairperson for half an hour. At the resumed meeting, the Chairperson thereafter addressed the equity shareholders and informed that the Meeting was held through VC in compliance with the directions of NCLT Order.

The remote e-Voting period, before the date of Meeting, commenced on Monday, June 23, 2025 (from 10:00 A.M. IST) and ended on Wednesday, June 25, 2025 (at 05:00 P.M. IST).

The Managing Director of the Company briefed the scheme of merger before the meeting.

In terms of the Notice, the resolution for following item of business was read and transacted at the Meeting:

 To consider and approve Scheme of Amalgamation and Arrangement between Dhanuka Laboratories Limited with Orchid Pharma Limited and their respective Shareholders and Creditors.

Pursuant to the Order, Ms. Vinitha Varshini. K, Advocate, was appointed as the Scrutinizer to scrutinize the voting through electronic means (i.e., remote e-voting and voting at the Meeting by using electronic system) ("e-voting").

The equity shareholders were informed that the voting results would be made available on the Company's website and also on the NSDL website within the prescribed timelines. The report would also be displayed on the notice board of the Company and forwarded to the National Stock Exchange of India Limited and BSE Limited, where the Company's shares are listed.

Voting by equity shareholders

The Company had provided remote e-voting facility to its equity shareholders to cast votes electronically on the business set out in the Notice of the Meeting.

The equity shareholders who did not cast their votes through remote e-Voting, were also provided facility to cast their vote during the course of Meeting. The e-Voting facility was kept open for 30 minutes post the conclusion of the proceedings of the meeting to enable the equity shareholders to cast their votes.

Thereafter, the Meeting was declared closed.